Blood Journals Portfolio/LinkedIn
Sep 9, 2025, 23:00
Blood Podcast Alert: LSD1 Inhibitors in SCD, Ruxolitinib+Dex in HLH, Low VWF Insights
Blood Journals Portfolio shared on LinkedIn:
”September is Sickle Cell Disease Awareness Month and together we are working to conquer SCD!
In this episode, “Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors in sickle cell disease; and clinical characteristics of patients with low von Willebrand factor” the methodology of three articles are discussed that feature sickle cell disease studies.
Key points are:
- Ruxolitinib plus Dexamethasone in Newly Diagnosed Adult Hemophagocytic Lymphohistiocytosis (HLH): A prospective study demonstrated that the combination of ruxolitinib and dexamethasone (Ru-D regimen) had a high response rate and led to favorable short-term survival outcomes in adult HLH patients. All patients responded to the treatment, and no significant adverse effects were observed.
- Lysine-Specific Demethylase-1 (LSD1) Inhibitors in Sickle Cell Disease: Novel, potent, and orally bioavailable LSD1 inhibitors have been shown to induce fetal hemoglobin synthesis in a sickle cell disease mouse model. These inhibitors effectively reduce reactive oxygen species and improve red blood cell lifespan, offering a promising new class of therapies for sickle cell disease and other beta-globinopathies.
- Clinical Characteristics of Patients with Low Von Willebrand Factor: Insights into the clinical phenotype and pathophysiological mechanisms underlying qualitative low von Willebrand factor (VWF) have been explored. Patients with plasma VWF levels between 30 to 50 IU/dL often present with mucocutaneous bleeding and may require tailored management strategies.
Listen to the full episode here.
What are your thoughts on these advancements in sickle cell disease research?”
Stay tuned for the podcast series in hematology with Hemostasis Today.
-
Apr 27, 2026, 23:24Leonardo Roever: The Emerging Role of the TyHGB Index in Predicting New-Onset Stroke
-
Apr 27, 2026, 20:25Shek Sady Khan: Addressing the Silent Burden of Venous Thromboembolism in Bangladesh
-
Apr 27, 2026, 16:04Heghine Khachatryan: Intracranial Hemorrhage in Leukemia – Beyond Thrombocytopenia
-
Apr 27, 2026, 15:56Marc Carrier: Supporting Thrombosis Canada in My Final Year as President
-
Apr 27, 2026, 15:52Tagreed Alkaltham։ You Think Eligibility Is About You… It’s Not
-
Apr 27, 2026, 15:52Emma Gasson: Top Abstract Oral Presentation at BSH 2026 on Cancer-Associated Thrombosis Microfluidics
-
Apr 27, 2026, 15:48Elliot Tapper: Continuing Anticoagulation Improves PVT Outcomes During Banding
-
Apr 27, 2026, 15:44Crisanto Torres: Early Plasma Administration Maximizes Survival in Traumatic Intracranial Hemorrhage
-
Apr 27, 2026, 15:38Key Insights from ESHMPN 26 on Advances in MPN Management – ESH